Bok-Nam Park1, Wooyoung Shim2, Young Hwan Ahn3, Jae-Ho Lee4, Young-Sil An1, Joon-Kee Yoon1. 1. Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon, 442-749 Republic of Korea. 2. Institute for Neuroregeneration and Stem Cell Research, Ajou University School of Medicine, Suwon, Republic of Korea ; Department of Molecular Science and Technology, Ajou University, Suwon, Republic of Korea. 3. Institute for Neuroregeneration and Stem Cell Research, Ajou University School of Medicine, Suwon, Republic of Korea ; Department of Neurosurgery, Ajou University School of Medicine, Suwon, Republic of Korea. 4. Department of Biochemistry, Ajou University School of Medicine, Suwon, Republic of Korea.
Abstract
PURPOSE: This study was performed to evaluate the effect of (111)In-labeling on the cell growth, cycle and viability of bone marrow mesenchymal stem cells (BMSCs). METHODS: Rat BMSCs were labeled with various doses of (111)In (0.4-11.1 Bq/cell). The growth curve of (111)In-BMSCs was obtained up to 14th day of labeling. The cell cycle was evaluated by 5-bromo-2-deoxyuridine (BrdU) labeling or propidium iodide (PI) staining. Senescent cells were counted under a light microscope after staining with 5-bromo-4-chloro-3-indolyl-D-galactopyranoside. Flow cytometry was performed to measure apoptotic and necrotic fractions after staining with annexin V-FITC and PI. RESULTS: The growth of BMSCs labeled with higher doses of (111)In (4.4 or 11.1 Bq/cell) was significantly inhibited from the 3rd day of labeling. Flow cytometry revealed less BrdU-positive BMSCs at 11.1 Bq (111)In/cell during all measurement days and G1 arrest at 4.4 and 11.1 Bq (111)In/cell. Significant increases in apoptosis and necrosis were also observed at 4.4 (3.04%/1.35%) and 11.1 Bq (111)In/cell (9.07%/3.18%) on the 14th day (control = 1.60%/0.39%). However, no cellular senescence was visualized up to the 14th day. CONCLUSION: A high dose of (111)In-labeling induced cell cycle arrest and death in BMSCs; therefore, it should be used with a careful dosimetry in case of applying it to humans.
PURPOSE: This study was performed to evaluate the effect of (111)In-labeling on the cell growth, cycle and viability of bone marrow mesenchymal stem cells (BMSCs). METHODS:Rat BMSCs were labeled with various doses of (111)In (0.4-11.1 Bq/cell). The growth curve of (111)In-BMSCs was obtained up to 14th day of labeling. The cell cycle was evaluated by 5-bromo-2-deoxyuridine (BrdU) labeling or propidium iodide (PI) staining. Senescent cells were counted under a light microscope after staining with 5-bromo-4-chloro-3-indolyl-D-galactopyranoside. Flow cytometry was performed to measure apoptotic and necrotic fractions after staining with annexin V-FITC and PI. RESULTS: The growth of BMSCs labeled with higher doses of (111)In (4.4 or 11.1 Bq/cell) was significantly inhibited from the 3rd day of labeling. Flow cytometry revealed less BrdU-positive BMSCs at 11.1 Bq (111)In/cell during all measurement days and G1 arrest at 4.4 and 11.1 Bq (111)In/cell. Significant increases in apoptosis and necrosis were also observed at 4.4 (3.04%/1.35%) and 11.1 Bq (111)In/cell (9.07%/3.18%) on the 14th day (control = 1.60%/0.39%). However, no cellular senescence was visualized up to the 14th day. CONCLUSION: A high dose of (111)In-labeling induced cell cycle arrest and death in BMSCs; therefore, it should be used with a careful dosimetry in case of applying it to humans.
Authors: Franz Josef Gildehaus; Florian Haasters; Inga Drosse; Erika Wagner; Christian Zach; Wolf Mutschler; Paul Cumming; Peter Bartenstein; Matthias Schieker Journal: Mol Imaging Biol Date: 2011-12 Impact factor: 3.488
Authors: Yuan Jin; Huafu Kong; Rob Z Stodilka; R Glenn Wells; Pamela Zabel; Peter A Merrifield; Jane Sykes; Frank S Prato Journal: Phys Med Biol Date: 2005-09-13 Impact factor: 3.609
Authors: Ramiro Flores-Ramírez; Artemio Uribe-Longoria; María M Rangel-Fuentes; Pedro Gutiérrez-Fajardo; Rosario Salazar-Riojas; Daniel Cervantes-García; José H Treviño-Ortiz; Genoveva J Benavides-Chereti; Luciana P Espinosa-Oliveros; Ramón H Limón-Rodríguez; Rogelio Monreal-Puente; Juan L González-Treviño; Augusto Rojas-Martínez Journal: Cardiovasc Revasc Med Date: 2010 Apr-Jun
Authors: V Caveliers; G De Keulenaer; H Everaert; I Van Riet; G Van Camp; S Verheye; J Roland; D Schoors; P R Franken; R Schots Journal: Q J Nucl Med Mol Imaging Date: 2007-03 Impact factor: 2.346
Authors: Michael Hofmann; Kai C Wollert; Gerd P Meyer; Alix Menke; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Wolfram H Knapp; Helmut Drexler Journal: Circulation Date: 2005-04-25 Impact factor: 29.690